Sg3 Management, LLC Relmada Therapeutics, Inc. Transaction History
Sg3 Management, LLC
- $0
- Q3 2023
A detailed history of Sg3 Management, LLC transactions in Relmada Therapeutics, Inc. stock. As of the latest transaction made, Sg3 Management, LLC holds 27,000 shares of RLMD stock, worth $78,300. This represents 0.14% of its overall portfolio holdings.
Number of Shares
27,000Holding current value
$78,300% of portfolio
0.14%Shares
0 transactions
| Quarter | Operation | Price Per share | shares change | shares Held | SEC Form |
|---|
Others Institutions Holding RLMD
# of Institutions
81Shares Held
12.3MCall Options Held
229KPut Options Held
138K-
Franklin Resources Inc San Mateo, CA1.3MShares$3.78 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.26MShares$3.64 Million0.0% of portfolio
-
Acadian Asset Management LLC Boston, MA1.19MShares$3.44 Million0.01% of portfolio
-
Parsons Capital Management Inc1MShares$2.91 Million0.21% of portfolio
-
Palo Alto Investors LP Palo Alto, CA732KShares$2.12 Million0.33% of portfolio
About RELMADA THERAPEUTICS, INC.
- Ticker RLMD
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 28,608,500
- Market Cap $83M
- Description
- Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that ...